Introduction
============

Breast cancer (BC) is the most common type of cancer and the leading cause of cancer death among females globally.[@b1-cmar-10-867] Hereditary factors are considered to play a key role in the genesis of breast cancer. Among all breast carcinomas, about 5%--10% are inherited, arising from genetic variants in susceptible genes.[@b2-cmar-10-867],[@b3-cmar-10-867] Single-nucleotide polymorphisms (SNPs) are the most frequent variation that occur in a single nucleotide at a specific position in the genome. Numerous SNPs have been identified through sequencing, and many of them in critical genes such as *BRCA1/2*, *TP53*, *TNF*, and *VEGF* were demonstrated to be associated with cancer susceptibility.[@b4-cmar-10-867]--[@b6-cmar-10-867]

*FOXP3* is a protein-coding gene located at human chromosome Xp11.23. Its product, forkhead box P3 (FoxP3), also known as scurfin, is specifically expressed in CD4^+^CD25^+^ regulatory T cells (Tregs) and functions mainly as a key regulator for the development and function of Tregs.[@b7-cmar-10-867],[@b8-cmar-10-867] As a member of the FOX family, FoxP3 also regulates transcription and DNA repair and is involved in cell growth and differentiation as well as embryogenesis.[@b9-cmar-10-867],[@b10-cmar-10-867] In addition to its critical function in immune response, *FOXP3* plays an important role in cancer development, although it is still a controversy whether it is an oncogene or tumor suppressor gene.[@b11-cmar-10-867],[@b12-cmar-10-867]

Nevertheless, several *FOXP3* SNPs have been reported to be associated with susceptibility to multiple cancers including lung cancer, hepatocellular carcinoma (HCC), and colorectal cancer.[@b13-cmar-10-867]--[@b15-cmar-10-867] Among these SNPs, rs3761548 and rs3761549 were the most common polymorphisms. Studies revealed that A allele and AA/AC genotype of rs3761548 significantly increased the risk of thyroid cancer, colorectal cancer, and non-small-cell lung cancer.[@b13-cmar-10-867],[@b15-cmar-10-867],[@b16-cmar-10-867] T allele of rs3761549 was found to be associated with susceptibility to lung cancer, while C allele was related with higher risk of HCC. In addition, TT/CT genotype was linked to an increased incidence of tumor recurrence in HCC.[@b17-cmar-10-867],[@b18-cmar-10-867] Here, we conducted a case--control study to explore the association of the two polymorphisms with BC risk in a Chinese Han population.

Methods
=======

Study subjects
--------------

Cases were selected from female BC patients treated at the Department of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong University (Xi'an, People's Republic of China). Healthy women who had a checkup at the hospital during the same period of time were recruited as controls. The criteria for enrollment were the same as our previous study.[@b19-cmar-10-867] Cases were confirmed by pathology, and controls were matched according to age and menopausal status. None of the cases had received chemotherapy or radiotherapy before surgery. Patients with other types of cancer were excluded. Finally, 560 patients and 583 healthy individuals were enrolled in our study. All of the subjects were from the Chinese Han population, had a mean age of 49 years, and were not related to each other.

Ethics statement
----------------

This study was approved by the Ethics Committee of Xi'an Jiaotong University. The purpose of this study was well informed to the subjects and written informed consent was obtained from each of them. Then, personal and clinical information of the subjects was collected from their medical records.

Genotyping assay
----------------

Peripheral blood of each subject was collected in tubes containing EDTA and stored at −80°C. Then, DNA was extracted from whole blood using the Universal Genomic DNA Extraction Kit (TaKaRa, Kyoto, Japan) according to the manufacturer's protocol, and the quantity of extracted DNA was assessed utilizing the UV/Vis spectrophotometer (DU530, Beckman Instruments, Brea, CA, USA). Two tag-SNPs (rs3761548 and rs3761549) were selected from the HapMap database, with minor allele frequency (MAF) \>0.01 in Chinese Han population. Sequenom MassARRAY Assay Design Software (version 3.0, Agena Bioscience, San Diego, CA, USA) was used to design multiplexed SNP MassEXTEND assay. And SequenomMassARRAY RS1000 was used to detect SNP genotyping.[@b20-cmar-10-867] Primers of the two SNPs are listed in [Table 1](#t1-cmar-10-867){ref-type="table"}. Data were analyzed with Sequenom Typer Software (version 4.0, Sequenom, San Diego, CA, USA).

Statistical analysis
--------------------

SPSS software (version 22.0, IBM Corporation, Armonk, NY, USA) was used for statistical analyses of data. The differences of basic parameters between the two groups were examined with Student *t*-test or χ^2^ test. For each SNP, Hardy--Weinberg equilibrium as well as the differences in allele frequencies between patients and healthy controls were examined by χ^2^ test. The association of SNPs with BC risk was evaluated by odds ratios (ORs) with 95% confidence intervals (CIs) for five different genetic models ("A" indicates the major allele and "a" indicates the minor allele): codominant model including homozygote (aa vs AA) and heterozygote (Aa vs AA), dominant model (Aa/aa vs AA), recessive model (aa vs AA/Aa), overdominant model (Aa vs AA/aa), and allele model (a vs A). *P*-values were adjusted by logistic regression analysis. All the tests were two-tailed, and *P*-value \<0.05 was considered statistically significant. We further calculated false-positive report probability (FPRP) to examine whether the significant findings were noteworthy. The prior probability of 0.1 was set in our study, and 0.5 was determined as a cut-off value for FPRP.[@b21-cmar-10-867],[@b22-cmar-10-867]

Results
=======

The basic characteristics of study subjects
-------------------------------------------

No significant difference was observed between the two groups in regards to age, menopausal status, and procreative times. However, the mean value of body mass index (BMI) in the patient group was significantly lower compared with that in control group (*P*=0.038). As obesity is also associated with BC risk,[@b23-cmar-10-867] BMI may be a confounding factor for the analysis. Therefore, the results were adjusted for BMI. The basic parameters of cases and controls are presented in [Table 2](#t2-cmar-10-867){ref-type="table"}.

Association of *FOXP3* SNPs with BC susceptibility
--------------------------------------------------

For both of the *FOXP3* polymorphisms, the genotype distribution in controls complied with Hardy--Weinberg equilibrium (*P*=0.895 and 0.934 respectively). In the overall analysis, *FOXP3*-rs3761548 was associated with a higher BC risk in heterozygous, dominant, overdominant, and allele genetic models (CA vs CC: OR =1.32, 95% CI =1.03--1.69, *P*=0.031; CA/AA vs CC: OR =1.32, 95% CI =1.04--1.69, *P*=0.023; CA vs CC/AA: OR =1.29, 95% CI =1.01--1.66, *P*=0.042; A vs C: OR =1.26, 95% CI =1.02--1.54, *P*=0.029). FPRP analysis showed that the associations were noteworthy. However, *FOXP3*-rs3761549 was not related to BC susceptibility ([Table 3](#t3-cmar-10-867){ref-type="table"}). We then carried out stratified analysis based on age and menopausal status in five genetic models. However, no relationship was observed between the two SNPs and BC susceptibility in either of the subgroups ([Table S1](#SD1-cmar-10-867){ref-type="supplementary-material"}).

Relationship between *FOXP3* SNPs and clinical features of BC
-------------------------------------------------------------

We also explored the relationship between the two *FOXP3* SNPs and BC clinical features, including tumor size, metastasis of lymph node, status of hormone receptor (estrogen receptor and progesterone receptor) as well as Her-2, and the expression level of Ki-67. We observed that CA, CA/AA genotype, and A allele of rs3761548 were related with a larger size of tumor (CA vs CC: OR =1.47, 95% CI =1.01--2.15; CA/AA vs CC: OR =1.54, 95% CI =1.07--2.23; A vs C: OR =1.48, 95% CI =1.08--2.03). In addition, the A allele was correlated with a positive status of Her-2 (A vs C: OR =1.36, 95% CI =1.01--1.85) ([Table 4](#t4-cmar-10-867){ref-type="table"}). As for rs3761549, there was still no significant association with BC clinicopathological features existing in any of the genetic models ([Table S2](#SD2-cmar-10-867){ref-type="supplementary-material"}).

Discussion
==========

*FOXP3* is a key gene in the immune system. It encodes a protein for a transcriptional regulator which belongs to the forkhead/winged-helix family. Defects in this gene can cause immunodeficiency syndrome.[@b8-cmar-10-867],[@b24-cmar-10-867] But the role of *FOXP3* in tumorigenesis has long been controversial. *FOXP3* was found to represses some oncogenes such as *MYC*, *HER2*, and *SATB1*. Its expression was downregulated in several tumors including breast, prostate, and ovarian tumors.[@b11-cmar-10-867],[@b12-cmar-10-867],[@b25-cmar-10-867] However, it was reported that most human tumors were infiltrated by Tregs with high FoxP3 labeling, and an excess of Treg activity can prevent the immune system from destroying cancer cells.[@b26-cmar-10-867],[@b27-cmar-10-867]

No matter what the exact role of this gene in tumor is, the genetic variation of *FOXP3* can indeed affect cancer susceptibility.[@b9-cmar-10-867],[@b26-cmar-10-867] The two common polymorphisms rs3761549 (C\>T) and rs3761548 (C\>A) were located in the promoter region of the *FOXP3* gene, which is considered to affect FoxP3 production and activity.[@b14-cmar-10-867] They were investigated in several tumors previously and were demonstrated to be associated with cancer susceptibility.[@b13-cmar-10-867],[@b15-cmar-10-867]--[@b18-cmar-10-867] However, the conclusions of the relationship between these two SNPs and BC susceptibility were controversial. Lopes et al[@b28-cmar-10-867] observed that the homozygote of rs3761548 was associated with triple-negative breast cancer risk in Brazilians (OR =3.78; 95% CI =1.02--14.06). Jahan et al[@b29-cmar-10-867] evaluated both rs3761548 and rs3761549 in an Indian population but failed to find any correlation with BC risk. However, the AA genotype of rs3761548 was significantly associated with advanced tumor stage (T3-T4) (OR =3.90; *p*=0.03),[@b29-cmar-10-867] whereas Zheng et al's[@b30-cmar-10-867] and Raskin et al's[@b31-cmar-10-867] study reported that neither rs3761548 nor rs3761549 were associated with BC. Among all these researchers, only Zheng et al[@b30-cmar-10-867] studied the Chinese population. However, their study evaluated just two genetic models (homozygotes and heterozygotes) and did not explore the relationship of these two SNPs with clinical parameters of BC.

Our study focused on a Chinese Han population and found that the CA, CA/AA genotype, and the A allele of rs3761548 can increase the risk of BC. Moreover, the A allele of rs3761548 was related with a larger size of tumor (≥2 cm). It was also correlated with a Her-2 positive status, indicating that patients with A allele of rs3761548 are more likely to have overexpression of *HER2*. It means that the polymorphism of this locus may be a potential biomarker for tumor subtype classification and help to guide treatment. The results were in accord with some of previous studies, suggesting that the A allele of rs3761548 is a risk factor for BC and may be involved in tumor progression. The mechanism of action is not clear, which is a potential subject for future studies. Maybe the critical location of this SNP could affect the production and activity of FoxP3, thus influencing tumorigenesis though FoxP3's function.

Some limitations could not be ignored in the study. First, selection bias is inevitable as this is a hospital-based, single-center study. Second, our sample size was insufficient to support stratified analysis for tumor subtypes. Finally, we did not analyze the impact of other risk factors such as lifestyle, radiation exposure to the chest, family history, and other benign breast lesions because of lacking relative data. Hence, population-based studies are required in the future to improve the accuracy of evaluation and to explore gene--environment interactions as well.

Conclusion
==========

To sum up, the present study suggests that the *FOXP3* polymorphism rs3761548 is associated with BC susceptibility in the Chinese and may be involved in tumor progression. Future studies in a large population with more races are needed to confirm the results. There is also a need to explore gene--environment interactions and possible mechanisms of action for this SNP.

Supplementary materials
=======================

###### 

Stratified analyses on association between *FOXP3* SNPs and BC risk

  SNPs                     Genotype   OR (95% CI)                                                                                                           
  ------------------------ ---------- ------------- ----- ----- ----- ----- ------------------- ------------------- ------------------- ------------------- -------------------
  rs3761548                C/C        C/A           A/A   C/C   C/A   A/A                                                                                   
  Age \<49 (n=604)         177        104           13    207   92    11    1.38 (0.60--3.16)   1.32 (0.94--1.87)   1.33 (0.95--1.85)   1.26 (0.55--2.85)   1.26 (0.95--1.67)
  Age ≥49 (n=536)          160        94            11    181   81    9     1.38 (0.56--3.42)   1.31 (0.91--1.89)   1.32 (0.93--1.88)   1.26 (0.51--3.09)   1.25 (0.93--1.69)
  Premenopausal (n=544)    159        94            11    187   83    10    1.29 (0.54--3.13)   1.33 (0.93--1.92)   1.33 (0.94--1.88)   1.17 (0.49--2.81)   1.25 (0.93--1.68)
  Postmenopausal (n=596)   178        104           13    201   90    10    1.47 (0.63--3.43)   1.30 (0.92--1.85)   1.32 (0.95--1.85)   1.34 (0.58--3.11)   1.26 (0.95--1.68)
  rs3761548                C/C        T/C           T/T   C/C   T/C   T/T                                                                                   
  Age \<49 (n=604)         202        82            10    198   100   12    0.82 (0.35--1.93)   0.80 (0.57--1.14)   0.81 (0.57--1.13)   0.87 (0.37--2.06)   0.85 (0.63--1.13)
  Age ≥49 (n=538)          183        74            9     174   87    11    0.78 (0.31--1.92)   0.81 (0.56--1.17)   0.81 (0.56--1.15)   0.83 (0.34--2.04)   0.83 (0.61--1.13)
  Premenopausal (n=544)    182        74            8     179   90    11    0.72 (0.28--1.82)   0.81 (0.56--1.17)   0.80 (0.56--1.14)   0.76 (0.30--1.93)   0.83 (0.61--1.12)
  Postmenopausal (n=598)   204        83            9     193   97    12    0.71 (0.29--1.72)   0.81 (0.57--1.15)   0.80 (0.57--1.12)   0.76 (0.31--1.83)   0.82 (0.61--1.10)

**Abbreviations:** BC, breast cancer; CI, confidence interval; FOXP3, forkhead box P3; OR, odds ratio; SNP, single-nucleotide polymorphism.

###### 

The association between rs3761549 and clinical features of BC

  Variables                           OR (95% CI)                                                                     
  --------------- ------------------- ------------------- ------------------- ------------------- ------------------- --
  Tumor size      \<2 cm              1.00                                                                            
  ≥2 cm           0.85 (0.28--2.59)   0.84 (0.59--1.18)   0.84 (0.60--1.18)   0.91 (0.30--2.75)   0.87 (0.65--1.17)   
  LN metastasis   (−)                 1.00                                                                            
  (+)             1.43 (0.63--3.25)   0.74 (0.52--1.05)   0.81 (0.58--1.13)   1.66 (0.74--3.71)   0.92 (0.71--1.19)   
  ER              (−)                 1.00                                                                            
  (+)             1.02 (0.40--2.59)   1.26 (0.88--1.79)   1.24 (0.88--1.75)   0.97 (0.39--2.43)   1.15 (0.86--1.54)   
  PR              (−)                 1.00                                                                            
  (+)             1.04 (0.35--3.07)   0.84 (0.59--1.18)   0.85 (0.60--1.19)   1.12 (0.38--3.26)   0.90 (0.67--1.19)   
  Her-2           (−)                 1.00                                                                            
  (+)             1.12 (0.33--3.79)   0.95 (0.65--1.37)   0.95 (0.66--1.38)   1.14 (0.34--3.84)   0.98 (0.71--1.33)   
  Ki-67           \<14%               1.00                                                                            
  ≥14%            0.59 (0.26--1.36)   0.72 (0.42--1.25)   0.68 (0.43--1.10)   0.62 (0.27--1.41)   0.68 (0.45--1.01)   

**Abbreviations:** BC, breast cancer; CI, confidence interval; ER, estrogen receptor; LN, lymph node; OR, odds ratio; PR, progesterone receptor.
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###### 

Primers used in this study

  SNP_ID      1st-PCRP                         2nd-PCRP                         UEP_SEQ
  ----------- -------------------------------- -------------------------------- ------------------
  rs3761548   ACGTTGGATGTGGGTGCTGAGGGGTAAACT   ACGTTGGATGAAGCCTAGATCTCAGGACTC   GCTCTCTCCCCAACTG
  rs3761549   ACGTTGGATGACATCACCTACCACATCCAC   ACGTTGGATGACCCCACAGGTTTCGTTCC    TTTCGTTCCGAGAACT

**Abbreviations:** SNP, single-nucleotide polymorphism; PCRP, primer for polymerase chain reaction; UEP_SEQ, primer for single nucleotide extension.

###### 

The comparison of basic characteristics between cases and controls

  Characteristics            Cases (560)   Controls (583)   *P*-value
  -------------------------- ------------- ---------------- -----------
  Age (years, mean ± SD)     49.09±11.02   48.80±8.28       0.612
   \<49                      294           311              
   ≥49                       266           272              
  Menopausal status                                         0.716
   Premenopausal             264           281              
   Postmenopausal            296           302              
  Procreative times                                         0.594
   \<2                       289           291              
   ≥2                        271           292              
  BMI (kg/m^2^, mean ± SD)   22.52±2.84    22.95±3.21       **0.038**

**Note:** *P*-value \<0.05 was shown in bold

**Abbreviation:** BMI, body mass index.

###### 

Genotype frequencies of *FOXP3* polymorphism in cases and controls

  Model                         Genotype   Cases (n, %)   Controls (n, %)   OR (95% CI)             *P*[a](#tfn4-cmar-10-867){ref-type="table-fn"}   FPRP
  ----------------------------- ---------- -------------- ----------------- ----------------------- ------------------------------------------------ -------
  rs3761548 (*P*~HWE~ =0.895)              559            581                                                                                        
  Codominant                    C/C        337 (60.3%)    388 (66.8%)       1.00                                                                     
  Heterozygote                  C/A        198 (35.4%)    173 (29.8%)       **1.32 (1.03--1.69)**   **0.031**                                        0.228
  Homozygote                    A/A        24 (4.3%)      20 (3.4%)         1.38 (0.75--2.55)       0.298                                            
  Dominant                      C/C        337 (60.3%)    388 (66.8%)       1.00                                                                     
                                C/A+A/A    222 (39.7%)    193 (33.2%)       **1.32 (1.04-1.69)**    **0.023**                                        0.228
  Recessive                     C/C+C/A    535 (95.7%)    561 (96.6%)       1.00                                                                     
                                A/A        24 (4.3%)      20 (3.4%)         1.26 (0.69--2.31)       0.456                                            
  Overdominant                  C/C+A/A    361 (64.6%)    408 (70.2%)       1.00                                                                     
                                C/A        198 (35.4%)    173 (29.8%)       **1.29 (1.01--1.66)**   **0.042**                                        0.328
  Allele                        C          872 (78.0%)    949 (81.7%)       1.00                                                                     
                                A          246 (22.0%)    213 (18.3%)       **1.26 (1.02--1.54)**   **0.029**                                        0.184
  rs3761549 (*P*~HWE~ =0.934)              560            582                                                                                        
  Codominant                    C/C        385 (68.8%)    372 (63.9%)       1.00                                                                     
  Heterozygote                  T/C        157 (28%)      187 (32.1%)       0.81 (0.63--1.05)       0.108                                            
  Homozygote                    T/T        18 (3.2%)      23 (4.0%)         0.76 (0.40--1.42)       0.386                                            
  Dominant                      C/C        385 (68.8%)    372 (63.9%)       1.00                                                                     
                                T/C-T/T    175 (31.2%)    210 (36.1%)       0.81 (0.63--1.03)       0.084                                            
  Recessive                     C/C-T/C    542 (96.8%)    559 (96.0%)       1.00                                                                     
                                T/T        18 (3.2%)      23 (4.0%)         0.81 (0.43--1.51)       0.503                                            
  Overdominant                  C/C-T/T    403 (72.0%)    395 (67.9%)       1.00                                                                     
                                T/C        157 (28.0%)    187 (32.1%)       0.82 (0.64--1.06)       0.132                                            
  Allele                        C          927 (82.8%)    931 (80.0%)       1.00                                                                     
                                T          193 (17.2%)    233 (20.0%)       0.83 (0.67--1.03)       0.088                                            

**Note:**

Adjusted for BMI. OR of significant association is presented in bold.

**Abbreviations:** BMI, body mass index; CI, confidence interval; FPRP, false-positive report probability; FOXP3, forkhead box P3; HWE, Hardy--Weinberg equilibrium; OR, odds ratio.

###### 

The association between rs3761548 and clinical features of BC

  Variables                            OR (95% CI)                                                                                 
  --------------- -------------------- ----------------------- ----------------------- ------------------- ----------------------- --
  Tumor size      \<2 cm               1.00                                                                                        
  ≥2 cm           2.51 (0.83--7.64)    **1.47 (1.01--2.15)**   **1.54 (1.07--2.23)**   2.19 (0.73--6.61)   **1.48 (1.08--2.03)**   
  LN metastasis   (−)                  1.00                                                                                        
  (+)             1.61 (0.59--4.40)    1.28 (0.90--1.83)       1.31 (0.92--1.85)       1.47 (0.55--3.99)   1.26 (0.94--1.69)       
  ER              (−)                  1.00                                                                                        
  (+)             0.59 (0.26--1.36)    0.76 (0.54--1.08)       0.74 (0.53--1.04)       0.66 (0.29--1.49)   0.77 (0.58--1.03)       
  PR              (−)                  1.00                                                                                        
  (+)             0.62 (0.30--1.27)    0.77 (0.54--1.10)       0.75 (0.53--1.05)       0.68 (0.34--1.38)   0.78 (0.59--1.02)       
  Her-2           (−)                  1.00                                                                                        
  (+)             2.34 (0.96--5.69)    1.29 (0.88--1.89)       1.37 (0.95--1.98)       2.13 (0.89--5.13)   **1.36 (1.01--1.85)**   
  Ki-67           \<14%                1.00                                                                                        
  ≥14%            1.05 (0.41--2.690)   0.96 (0.67--1.38)       0.97 (0.68--1.38)       1.07 (0.43--2.70)   0.98 (0.73--1.32)       

**Note:** OR of significant association is presented in bold.

**Abbreviations:** BC, breast cancer; CI, confidence interval; ER, estrogen receptor; LN, lymph node; OR, odds ratio; PR, progesterone receptor.
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